Our Pipeline
We are rapidly advancing a number of antigen-targeted
combinations towards the clinic.
Partnering
CAPAC can unlock the potential of your therapeutic target
Our technology can transform antigen-targeted drugs, increasing the activity and lowering the toxicities. Since we don’t rely on internalization for activation, this expands the targets that can be reached.
Our collaborations advance novel therapeutics to bring transformative therapies to the clinic. We have validated CAPAC against a wide range of different targets and activator types, with a variety of payloads.
Targeting Activators
Payloads
Monoclonal antibodies
Antibody fragments
Traditional chemotherapy
Peptides
Highly toxic agents
Small molecules
Radiotherapeutics
Biopolymer
Immune agonists
We have recently announced a strategic research collaboration with Johnson & Johnson Enterprise Innovation Inc. to develop a novel therapeutic based on our biopolymer activator.
If you are interested in exploring a collaboration, contact us at bd@shasqi.com
